ALDOA Promotes Glycolysis and NLRP3 / GSDMD Pyroptosis to Accelerate ALS Progression
Annals of Clinical and Translational Neurology · 2026
DOI: 10.1002/acn3.70372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Kaixin Yan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Glycolysis, Amyotrophic Lateral Sclerosis, Fructose-Bisphosphate Aldolase, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Xinjiang Uygur Autonomous Region Health Commission "Tianshan Talent" High-Level Medical and Health Personnel Project.
Abstract (Originalsprache)
Objective
Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Methods
In vivo, tamoxifen‐induced TDP‐43 cKO mice were assessed for motor function (rotarod/suspension tests), motor cortex L‐lactic acid, and ALDOA/NLRP3/GSDMD expression. The ALDOA inhibitor Aldometanib was administered. In vitro, TDP‐43 KO NSC34 cells were used to measure viability, glucose uptake, and L‐lactic acid.
Results
ALS model mice exhibited significant motor deficits, progressive weight loss, and reduced survival. Their motor cortex showed elevated ALDOA expression, L‐lactic acid accumulation, and NLRP3/GSDMD inflammasome activation. Aldometanib treatment suppressed glycolysis, prolonged survival, and slowed disease progression by inhibiting NLRP3/GSDMD‐mediated pyroptosis. In vitro, TDP‐43‐deficient NSC34 cells displayed increased ALDOA levels, enhanced glycolytic flux, NLRP3/GSDMD pathway activation, and impaired proliferation.
Conclusion
We show that ALDOA‐mediated glycolytic dysregulation activates the NLRP3/GSDMD inflammasome, leading to pyroptosis in motor neurons. Pharmacological inhibition of ALDOA alleviates glycolytic dysregulation and extends survival, identifying ALDOA as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
- Department of Neurology, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
- Department of Neurology, Xiangya Hospital Central South University, Changsha, China.
ORCID-Profile: Kaixin Yan, Yuxuan Yong, Fangfang Bi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Xinjiang Uygur Autonomous Region Health Commission "Tianshan Talent" High-Level Medical and Health Personnel Project
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
Zitieren
APA
Yan, K., Jiang, Y., Yong, Y., Zhang, T., Zhang, N., Zeng, Q., Gong, X., Meng, L., Bi, F., & Liu, Y. (2026). ALDOA Promotes Glycolysis and NLRP3 / GSDMD Pyroptosis to Accelerate ALS Progression. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70372
Vancouver
Yan K, Jiang Y, Yong Y, Zhang T, Zhang N, Zeng Q, et al. ALDOA Promotes Glycolysis and NLRP3 / GSDMD Pyroptosis to Accelerate ALS Progression. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70372
BibTeX
@article{Yan2026,
author = {Yan, Kaixin and Jiang, Yan and Yong, Yuxuan and Zhang, Tianshuo and Zhang, Niannian and Zeng, Qianqian and Gong, Xue and Meng, Li and Bi, Fangfang and Liu, Yongmin},
title = {ALDOA Promotes Glycolysis and NLRP3 / GSDMD Pyroptosis to Accelerate ALS Progression},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70372}
}
EUVIMED